Contract Research and Development Organizations

Contract Research and Development Organizations

Author: Shayne C. Gad

Publisher: Springer Science & Business Media

Published: 2011-08-04

Total Pages: 213

ISBN-13: 146140049X

DOWNLOAD EBOOK

The last 10 years have seen a seismic shift in therapeutic product development and testing. In both the pharmaceutical (both small and large molecule) and medical device sectors, the vast majority of testing and evaluation of products is not performed within innovator companies, but rather has been outsourced to a growing universe of commercial organizations. The authors both have more than 30 years experience in this field, and both have worked within innovator companies, for CROs, and as consultants in the field. Contract Research and Development Organizations: Their Role in Global Product Development has been crafted by these authors to provide a how to guide for all aspects of working with CROs in selecting, working with and ensuring the best possible desirable outcome of having the R&D function, or substantial parts of it, outsourced. It uses as the exemplary case nonclinical safety assessment, biocompatibility and efficacy testing which are to be performed to select the best possible candidate compound, device or formulation and then moving the resulting regulated therapeutic medical product into and through the development process and to marketing approval. But also covered are the contract synthesis of drug substances and corresponding manufacture of biologics and manufacture of products, formulation development, clinical evaluation, regulatory and document preparation support, and use of consultants. Included in the volume are an exhaustive listing of those CROs in the (drug and device) safety evaluation sector and their contact information and capabilities, and extensive similar listing for the other types of contract service providers. Also included are guidances on how to monitor ongoing work at contract facilities and audit check lists for GLP, GMP and GCP facilities. These listings are international in scope, and a specific chapter addresses working with some of the newer international CROs.


University-Industry Technology Transfer in the UK: Emerging Research and Opportunities

University-Industry Technology Transfer in the UK: Emerging Research and Opportunities

Author: Wynn, Martin

Publisher: IGI Global

Published: 2018-12-21

Total Pages: 229

ISBN-13: 1522574093

DOWNLOAD EBOOK

Since the turn of the century, technology transfer and innovation has played an increasingly important role in government policy for reinvigorating and supporting a country's industry. This has been fueled by technology transfer from third parties such as universities, but due to the rapid evolution of the external environment of technology, companies require regular upgrades to information systems and technical infrastructure and adjustments. University-Industry Technology Transfer in the UK: Emerging Research and Opportunities provides innovative insights into how technology transfer has operated in university-company projects undertaken in small- to medium-sized enterprises. Highlighting 19 different cases drawn from companies in the regions adjoining the University of Gloucestershire, UK, from a qualitative case study approach, the content within this publication analyzes contract packers, the manufacturing industry, and research organizations. It is a vital reference source for managers, business owners, education administrators, researchers, academicians, professionals, policymakers, and graduate-level students seeking coverage on topics centered on case examples of technology transfer projects in different industry sectors.


Research Handbook on Intellectual Property Licensing

Research Handbook on Intellectual Property Licensing

Author: Jacques de Werra

Publisher: Edward Elgar Publishing

Published: 2013-01-01

Total Pages: 519

ISBN-13: 1781005982

DOWNLOAD EBOOK

'Transactions involving intellectual property whether by way of out-and-out assignment or by one of the myriad variants of licensing which are possible, are really really important – they help the world of business go round. But such transactions can be complex with things like national rules preventing alienation getting in the way of bargains people wish to make. So it is quite astonishing how sparse the literature on the subject is – particularly literature taking a comparative view. This book is perhaps the very first of its kind, taking as it does perspectives from the major legal systems of the world. Moreover its distinguished authors have not written in a technical or abstruse way – as academics (and some judges) can all too easily do. Far from it. This book is readable – and anyone concerned with intellectual property licensing should read it and will find it a pleasure to do so. They will also learn a lot about some of the pitfalls and bear-traps to be found around the world. At UCL we have recognised the importance of this subject. This book will be on our students' reading list.' – The Rt. Hon. Sir Robin Jacob, UCL Faculty of Laws, UK 'IP licensing underpins the information economy. This impressive book brings together leading academic lawyers and practitioners from a range of key jurisdictions to explore a number of major current issues. The book is both thoughtful and practical and it is not afraid to call for greater harmonization of IP licensing law. It is a must have for all those involved in the field.' – Simon Stokes, Blake Lapthorn 'This Research Handbook provides a valuable mix of practical and theoretical perspectives on IP licensing and will serve as a reference resource for scholars and practitioners in this field of study.' – Francesco Parisi, University of Minnesota, US and University of Bologna, Italy 'The Handbook brings together a unique collection of world renowned experts providing detailed discussion in every chapter. The brilliance of this collective work is found in its broad two dimensional focus – beyond patents to all key IP assets on the one hand, and country specific discussion for key regions around the world on the other. . . Whether read cover-to-cover as a compilation of current best practice or used as a true reference guide, the Research Handbook on Intellectual Property Licensing is a must have for anyone seeking to capture value from intangible assets.' – From the foreword by James E. Malackowski The Research Handbook on Intellectual Property Licensing explores the complexities of intellectual property licensing law from a comparative perspective through the opinions of leading experts. This major research tool analyses the features of specific types of licensing agreements and also addresses other practical issues which apply across different types of licensing transactions, such as the treatment of licensing in bankruptcy and the use of arbitration for solving licensing disputes. The Handbook ultimately provides a scholarly contribution to the development of global intellectual property licensing policies. Including transversal and comparative analysis, this Handbook will appeal to intellectual property licensing practitioners, lawyers and intellectual property and contract law academics.


Description and Analysis of the VA National Formulary

Description and Analysis of the VA National Formulary

Author: Institute of Medicine

Publisher: National Academies Press

Published: 2000-10-03

Total Pages: 280

ISBN-13: 0309183537

DOWNLOAD EBOOK

The VA National Formulary generated controversy, which motivated congressional scrutiny and a directive to the VA to commission this report reviewing the experience with the National Formulary and formulary system. This Institute of Medicine committee was pleased to assist the Congress with this review, in part because the committee saw in the VHA example an opportunity to understand and anticipate problems that all publicly funded programs are likely to encounter in this new age of pharmaceuticals. The Congress asked the committee to review the restrictiveness of the National Formulary, its impact on the costs and quality of care in the VHA, and how it compared to formularies and drug management practices in the private sector and in other public programs, especially Medicaid. Detailed in the pages that follow, the committee's findings and conclusions on these questions are, the committee believes, highly instructive, though not always in the ways that we anticipated.


European Collaboration: Towards Drug Developement and Rational Drug Therapy

European Collaboration: Towards Drug Developement and Rational Drug Therapy

Author: F.C. Tulunay

Publisher: Springer Science & Business Media

Published: 2012-12-06

Total Pages: 180

ISBN-13: 3642554547

DOWNLOAD EBOOK

“European Collaboration: Towards Drug Development and Rational Drug Therapy “ is the title of the 6th Congress of the European Association for Clinical Pharmacology and Therapeutics ( EACPT )being held in Istanbul,Turkey from June 24th -28th 2003. Istanbul has been chosen as the venue for this congress as a unique city bridging two continents and bringing together scientists from a large number of countries. This volume has been edited by Prof Cankat Tulunay ( the President of the Congress ) and Prof Michael Orme ( co-ordinator of the Scientific Committee and Hon. Secretary of EACPT. The volume contains details of the 21 symposia and 3 workshops that are taking place in Istanbul together with the abstracts from the more than 400 submitted and being presented in Istanbul. The organisers hope that you will enjoy both the scientific and cultural aspects of this Congress. Table of contents Abstracts of lectures 1 Table of abstracts 39 Abstracts 69 Abstracts of lectures 23 June 2003 Whole Day Course indeed it is important to stress that this process in Introduction to the Methodology of Clinical Trials a continuum, with useful information coming from different departments contributing day by Paola Antonini day to the final product profile. Key areas of Pre- Medical Affairs Director, Merck Sharp & Dohme clinical Development are Pharmacology, Toxicol- Italy ogy, Pharmacokinetics and Chemistry and Ph- macy.


Drug Discovery and Clinical Research

Drug Discovery and Clinical Research

Author: SK Gupta

Publisher: JP Medical Ltd

Published: 2011-06

Total Pages: 659

ISBN-13: 9350252724

DOWNLOAD EBOOK

The Drug Discovery and Clinical Research bandwagon has been joined by scientists and researchers from all fields including basic sciences, medical sciences, biophysicists, biotechnologists, statisticians, regulatory officials and many more. The joint effort and contribution from all is translating into the fast development of this multi-faceted field. At the same time, it has become challenging for all stakeholders to keep abreast with the explosion in information. The race for the finish-line leaves very little time for the researchers to update themselves and keep tabs on the latest developments in the industry. To meet these challenges, this book entitled Drug Discovery and Clinical Research has been compiled. All chapters have been written by stalwarts of the field who have their finger on the pulse of the industry. The aim of the book is to provide succinctly within one cover, an update on all aspects of this wide area. Although each of the chapter dealt here starting from drug discovery and development, clinical development, bioethics, medical devices, pharmacovigilance, data management, safety monitoring, patient recruitment, etc. are topics for full-fledged book in themselves, an effort has been made via this book to provide a bird’s eye view to readers and help them to keep abreast with the latest development despite constraints of time. It is hoped that the book will contribute to the growth of readers, which should translate into drug discovery and clinical research industry’s growth.


NESINA Drug Profile, 2023

NESINA Drug Profile, 2023

Author: DrugPatentWatch

Publisher: DrugPatentWatch.com

Published: 2023-08-15

Total Pages: 100

ISBN-13: 1934899852

DOWNLOAD EBOOK

NESINA Drug Profile, 2023

This report focuses on NESINA and covers the following critical aspects of this drug:

  • United States patents
  • Expired United States patents
  • FDA Paragraph IV patent challenges
  • District Court patent litigation
  • European supplementary protection certificates (SPCs)
  • Clinical trials
  • Drug prices
  • Finished product suppliers
  • Raw active pharmaceutical ingredient (API) sources